On August 5th, the U.S. Food and Drug Administration (FDA) released two regulatory science policy memoranda regarding Pre-Market Tobacco Product Applications (PMTAs) for new e-cigarette products.
Two memorandums were published on June 3rd of this year, titled "Genotoxicity hazard identification and carcinogenicity stratification of components in tobacco products intended for sale of electronic nicotine delivery systems (ENDS)" and "Calculation of excessive lifetime cancer risk in tobacco products intended for sale of ENDS
Overall, these scientific policy memoranda provide an internal overview of the FDA's thoughts on a specific topic at a particular point in time. As policies, regulatory frameworks, or the science of regulation evolve, the information in the memoranda may change, and the memoranda are continuously being updated.
The FDA's review of tobacco product applications is based on specific facts within each application and documented in each application's specific review. Therefore, the two memos released today should not be used as tools, guides, or manuals for preparing or submitting applications to the FDA.
For applicants seeking approval for new tobacco products in the market, the FDA has released final regulations, such as the PMTA final rule, which specifically describes the content, format, review process and guidance documents required for PMTAs. Additionally, the FDA regularly posts more related resources on its website and social media platforms in its Center for Tobacco Products (CTP), such as webinars and application tips.
It has been reported that in April of this year, the FDA resumed issuing regulatory science policy memoranda, and released another in May. The latest memorandum reflects CTP's commitment to enhancing regulatory transparency.
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
